Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
NCT07235020
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Uncomplicated Plasmodium Falciparum Malaria
Interventions
DRUG:
INE963
Sponsor
Novartis Pharmaceuticals